

Express Mail Label No. EV 682424481 US Dated: September 29, 2006

Docket No.: CDJ-166RCE
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Yashwant M. Deo *et al.*

Application No.: 09/851614

Confirmation No.: 4957

Filed: May 8, 2001

Art Unit: 1644

For: HUMAN MONOCLONAL ANTIBODIES TO
DENDRITIC CELLS

Examiner: G. R. Ewoldt

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (SIDS)

Dear Sir:

In accordance with 37 CFR 1.97, Applicants hereby make of record the following additional documents. A PTO Form SB/08 and a full copy of each of the documents required under 37 CFR 1.98(a)(2) accompany this statement.

This Information Disclosure Statement is filed more than three months after the U.S. filing date, and after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Office Action or Notice of Allowance (37 CFR 1.97(c)).

Applicants have not submitted copies of each cited U.S. patent and U.S. patent application in accordance with 37 CFR 1.98(a)(2)(ii). Applicants submit herewith copies of foreign patents and non-patent references in accordance with 37 CFR 1.98(a)(2).

This statement is not to be interpreted as a representation that the cited documents are material, that an exhaustive search has been conducted, or that no other relevant information exists. Nor shall the citation of any document herein be construed *per se* as a representation that

10/04/2006 WABDEL1 000000050 120080 09851614
02 FEB 2007 100,000
10/04/2006 WABDEL1 000000050 120080 09851614


such document is prior art. Moreover, Applicants understand the Examiner will make an independent evaluation of the cited documents.


Please charge our Deposit Account No. 12-0080 in the amount of \$180.00 covering the fee set forth in 37 CFR 1.17(p). The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 12-0080, under Order No. CDJ-166RCE.

Dated: September 29, 2006

Respectfully submitted,

JMD/JGS/mch

By 
Jeanne M. DiGiorgio
Registration No.: 41,710
LAHIVE & COCKFIELD, LLP
28 State Street
Boston, Massachusetts 02109
(617) 227-7400
(617) 742-4214 (Fax)
Attorney/Agent For Applicant



SEP 29 2006

PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete if Known	
				Application Number	09/851614-Conf. #4957
				Filing Date	May 8, 2001
				First Named Inventor	Yashwant M. DEO
				Art Unit	1644
				Examiner Name	G. R. Ewoldt
Sheet	1	of	2	Attorney Docket Number	CDJ-166RCE

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
A1*		US-5,869,057	02-09-1999	Rock	
A2*		US-6,080,409	06-27-2000	Laus et al.	
A3*		US-6,277,959	08-21-2001	Valladeau et al.	

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)			
	B1	WO-92/07579-A1	05-14-1992	The Children's Medical Center Corporation	
	B2	WO-93/04187-A1	03-04-1993	Medical Research Council	
	B3	WO-96/23882-A1	08-08-1996	The Rockefeller University	
	B4	WO-97/45449-A1	12-04-1997	Hart, Derek et al.	
	B5	WO-99/02562-A1	01-21-1999	Schering Corporation	
	B6	WO-99/16455-A1	04-08-1999	The Austin Research Institute	
	B7	WO-99/24554-A2	05-20-1999	University of Pittsburgh	
	B8	WO-99/47673-A2	09-23-1999	Schering Corporation	
	B9	WO-99/58678-A2	11-18-1999	Micromet GmbH	
	B10	WO-00/00156-A2	01-06-2000	Trustees of Dartmouth College	
	B11	WO-00/00592-A1	01-06-2000	Bae, Yong Soo et al.	
	B12	WO-00/18803-A2	04-06-2000	Schering Corporation	
	B13	WO-01/85798-A2	11-15-2001	Medarex, Inc.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with a single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
	C1	Berlyn, Kathleen A. et al, "Generation of CD4 ⁺ and CD8 ⁺ T Lymphocyte Responses by Dendritic Cells Armed with PSA/Anti-PSA (Antigen/Antibody) Complexes," <i>Clinical Immunology</i> , Vol. 101(3):276-283 (2001)			
	C2	Chien, Nadine C. et al, "Significant structural and functional change of an antigen-binding site by a distant amino acid substitution: Proposal of a structural mechanism," <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 86:5532-5536 (1989)			
	C3	Geissmann, Frédéric et al, "A Subset of Human Dendritic Cells Expresses IgA Fc Receptor (CD89), Which Mediates Internalization and Activation Upon Cross-Linking by IgA Complexes," <i>The Journal of Immunology</i> , Vol. 166:346-352 (2001)			
	C4	Hawiger, Daniel et al, "Dendritic Cells Induce Peripheral T Cell Unresponsiveness Under Steady State Conditions In Vivo," <i>J. Exp. Med.</i> , Vol. 194(6):769-779 (2001)			
	C5	Kawakami, Yutaka et al, "The Use of Melanosomal Proteins in the Immunotherapy of			
Examiner Signature		Date Considered			



PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete if Known	
				Application Number	09/851614-Conf. #4957
				Filing Date	May 8, 2001
				First Named Inventor	Yashwant M. DEO
				Art Unit	1644
				Examiner Name	G. R. Ewoldt
Sheet	2	of	2	Attorney Docket Number	CDJ-166RCE

		Melanoma," <i>Journal of Immunotherapy</i> , Vol. 21(4):237-246 (1998)	
	C6	Potter, Kathleen N. et al, "Evidence for Involvement of a Hydrophobic Patch in Framework Region 1 of Human V4-34-Encoded Iggs in Recognition of the Red Blood Cell I Antigen," <i>The Journal of Immunology</i> , Vol. 169:3777-3782 (2002)	
	C7	Rudikoff, Stuart et al, "Single amino acid substitution altering antigen-binding specificity," <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 79:1979-1983 (1982)	
	C8	Sallusto, Federica et al, "Dendritic Cells Use Macropinocytosis and the Mannose Receptor to Concentrate Macromolecules in the Major Histocompatibility Complex Class II Compartment: Downregulation by Cytokines and Bacterial Products," <i>J. Exp. Med.</i> , Vol. 182:389-400 (1995)	
	C9	Tempest, Philip R. et al, "A Humanized Anti-Tumor Necrosis Factor- α Monoclonal Antibody That Acts as a Partial, Competitive Antagonist of the Template Antibody," <i>Hybridoma</i> , Vol. 13(3):183-190 (1994)	
	C10	Tjoa, Benjamin et al, "Development of dendritic-cell based prostate cancer vaccine," <i>Immunology Letters</i> , Vol. 74:87-93 (2000)	
	C11	Tüting, Thomas et al, "Autologous Human Monocyte-Derived Dendritic Cells Genetically Modified to Express Melanoma Antigens Elicit Primary Cytotoxic T Cell Responses In Vitro: Enhancement by Cotransfection of Genes Encoding the Th1-Biasing Cytokines IL-12 and IFN- α 1," <i>The Journal of Immunology</i> , Vol. 160:1139-1147 (1998)	
	C12	Wang, Hui et al, "Rapid antibody responses by low-dose, single-step, dendritic cell-targeting immunization," <i>PNAS</i> , Vol. 96(2):847-852 (2000)	
	C13	FRELTA D et al., "Class II-targeted antigen is superior to CD40-targeted antigen at stimulating humoral responses in vivo", <i>International Immunopharmacology</i> , February 2001, vol. 1, 1, no. 2, pages 265-275	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	Date Considered
--------------------	-----------------